Previous close | 1.9100 |
Open | 2.0600 |
Bid | 1.3500 x 100 |
Ask | 1.4800 x 100 |
Day's range | 1.3200 - 2.0700 |
52-week range | 1.0200 - 9.9000 |
Volume | |
Avg. volume | 2,063,159 |
Market cap | 5.994M |
Beta (5Y monthly) | 2.84 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Proposed all stock merger values VivoPower equity at US$556 million (implying a share price of US$101 per VVPR share) with FAST equity valued at US$578 million VivoPower expected to issue 5.72 million restricted shares at US$101 per VivoPower share as consideration for FAST VivoPower shareholders expected to own 49% of the pro forma combined group, with affiliates and insiders agreeing to a voluntary lock up upon closing of the transaction Post-proposed merger, VivoPower will have an estimated 1
Sansure Biotech Inc (“Sansure”) is a US$1.4bn market capitalisation in vitro diagnostic solutions company listed on Shanghai Stock Exchange Mpox virus footprint has significant overlap with key markets where VivoPower operates, including the Asia Pacific region, Australasia, Africa and the Middle East The Singapore government has already introduced quarantine measures to contain the spread of the Mpox virus, with risk of other countries following suit Distribution agreement is part of VivoPower’
Annual consolidated revenue of $11.8 million down 22% year-on-year (“y-o-y”) reflecting a strategic focus towards the Electric Vehicle and Sustainable Energy Solutions business units and discontinuation and sale of Critical Power business units in Australia Underlying consolidated adjusted EBITDA1 from continuing operations declined slightly to a ($5.9) million loss from a ($5.7) million loss in FY23 Cash balance at June 30, 2024 was $0.8m in comparison to $0.6m at June 30, 2023 Tembo E-LV, a su